Osteoporosis (significant bone thinning) is a common side effect of Androgen Deprivation therapy, a widely used and effective treatment for advanced prostate cancer. Androgen Deprivation stops the production of testosterone and can result in the onset of osteoporosis, which often … Continue reading →

Bayer proudly announced yesterday afternoon that Alpharadin had received FDA approval, after finishing the Phase 3 trials. This approval comes three months ahead of schedule. Bayer (per usual drug maker practices) changed the name from Alpharadin to Xofigo® immediately. So, … Continue reading →

One of a lucky few, The University of New Mexico Cancer Center, is facilitating a Phase 3 Prostate Cancer Research Program which will study the effects of combining gene therapy and immunotherapy. This process includes a combination of injecting an … Continue reading →

The Affordable Care Act was enacted to make sure all Americans have access to affordable and quality healthcare. However, it appears that cancer patients and others with life-altering, chronic diseases could face exceedingly high costs for medications. Under President Obama’s … Continue reading →

According to Dr. Mark A Moyad (MD., MPH, and Co-Director of the Men’s Health Program at the University of Michigan), whom you may recognize from his outstanding string of 60+ consecutive articles in our quarterly newsletter, is predicting that by … Continue reading →

In our efforts to create a politically correct country, we have veered hard off the course of common sense. We (at the risk of sounding completely like a conspiracy theorist nut case I’m going to use we, they and other … Continue reading →

After reading a recent article, something jumped out at me. During a recent study, the support for early screening was illustrated, although it wasn’t the main focus of the study. The primary focus was that “men who are uninsured or … Continue reading →